{"entity":{"id":"nct06209580","kind":"trial","name":"AMT-253 in Patients With Advanced Solid Tumours","aka":[],"tldr":"A phase 1/2 trial of AMT-253 for injection in melanoma, run by Multitude Therapeutics Inc., now recruiting.","summary":"AMT-253 in Patients With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06209580 by Multitude Therapeutics Inc., with 96 participants planned, started 2024-01-31 and due to reach its primary completion in 2026-04-30. Interventions recorded: AMT-253 for injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06209580","url":"https://clinicaltrials.gov/study/NCT06209580"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["multitude-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06209580","phase":"1/2","setting":"Phase I/II Study of AMT-253 in Patients With Unresectable or Metastatic Malignant Melanoma and Other Advanced Solid Tumors","sponsor":"Multitude Therapeutics Inc.","enrolled":96,"outcomes":[]},"route":"/trials/nct06209580/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"company":[{"id":"multitude-therapeutics","kind":"company","name":"Multitude Therapeutics","route":"/companies/multitude-therapeutics/"}]}}